ArticleKidney3602026
Ergothioneine Depletion in Peritoneal Dialysis.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Depletion of the Antioxidant Ergothioneine by Critical Illness and Continuous Renal Replacement Therapy.Kidney and dialysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
key pointsHemodialysis has been shown to greatly deplete ergothioneine, a diet-derived antioxidant. Peritoneal dialysis, which provides lower clearance of solutes, also depletes ergothioneine but to a lesser extent than hemodialysis. Whether ergothioneine repletion benefits people receiving dialysis remains to be tested.
backgroundDialysis may deplete the body of valuable solutes. We previously found that the diet-derived antioxidant ergothioneine was markedly depleted in patients on hemodialysis. Standard peritoneal dialysis (PD) prescriptions provide lower clearance of small molecules than standard hemodialysis prescriptions. We, therefore, tested whether ergothioneine would be depleted in patients on PD but to a lesser degree than in patients on hemodialysis.
methodsBlood levels of ergothioneine were compared in 16 patients on PD, 16 patients on hemodialysis, and 15 controls with normal kidney function. Levels were measured using liquid chromatography-mass spectrometry in plasma and also in erythrocytes in which ergothioneine is normally highly concentrated. Ergothioneine clearances by PD and hemodialysis were also compared.
resultsErythrocyte ergothioneine levels were much lower in both patients on PD and patients on hemodialysis than controls. The erythrocyte levels in patients on PD averaged 34% of those of controls, whereas levels in patients on hemodialysis averaged only 10% of those of controls. Plasma ergothioneine levels in patients on dialysis were also lower than controls. The time-averaged clearance of ergothioneine was lower with PD than with hemodialysis, so that a standard PD regimen would remove less ergothioneine daily than a standard hemodialysis regimen at a given plasma level.
conclusionsThe antioxidant ergothioneine is depleted in patients on PD but to a lesser extent than in patients on hemodialysis. Benefits of ergothioneine repletion in patients on dialysis remain to be assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.